Dendrimer-Aptamer Conjugation Service

Dendrimers conjugated with aptamers can be used as non-viral vectors to enhance targeting of tumor cells by complexing with various anti-cancer agents. CD BioSciences has been involved in dendrimer-related research for many years and uses a comprehensive and proven dendrimer modification platform to provide dendrimer-aptamer conjugation services to customers worldwide.

Aptamers for Precision Therapy

Aptamers are synthetic, short, single-stranded RNA or DNA molecules of 20-28 nucleotides with variable regions of ∼40 100 nucleotide bases that can fold and produce secondary or three-dimensional structures. Aptamers are considered to be "smart ligands" and are often referred to as "nucleic acid antibodies". In contrast to antibodies, aptamers can bind to functional domains of their cognate target protein. The recognition of target molecules by aptamers utilizes their secondary or tertiary structure. Interaction with small molecules (e.g., amino acids) induces a structural switch, changing the internal loop structure of the aptamer, compared with the arrangement when binding with large molecules (e.g., enzymes, proteins, growth factors or monoclonal antibodies). Advantages of aptamers over conventional antibodies in clinical use include low immunogenicity, high cell/tissue selectivity and permeability to numerous potential targets; advantages in drug development include thermal stability, low batch variation, short production time and low cost. Due to their high affinity, specific targeting and low immunogenicity, aptamers are widely used as ligands for drug targeting systems in cancer therapy. Aptamers can recognize various biomolecules such as peptides/proteins and cellular receptors when used as ligands. Aptamer-based drug delivery systems can target specific receptors on cancer cells to achieve precision therapy.

2D schematic representation of aptamer function. (Mignani S, et al., 2020)

Dendrimer-Aptamer Conjugation for Tumor Targeted Therapy

As a unique class of polymers, dendrimers have a highly branched three-dimensional structure whose properties and size can be precisely controlled. Polymer size is one of the most important parameters to be evaluated, as it determines the clear kinetics, biodistribution and in vivo efficacy of the polymer. Nanomaterials larger than 200 nm in size typically elicit an immune response and are taken up by Kupffer cells of the mononuclear phagocytic system. In contrast, smaller nanomaterials (<150 nm) cause rapid clearance from the circulation, and nanomaterials <10 nm are easily cleared through the kidneys or lymph nodes. One of the main problems when dendrimers are used as drug delivery systems is the inability to distinguish between target and non-target cells for targeted drug delivery, which can easily lead to off-target effects. Aptamers can be used for diagnostics, precision medicine and personalized medicine. When conjugated with aptamers as ligands to dendrimers, they can be used as non-viral carriers for targeted delivery of drugs to tumor cells.

Dendrimers conjugated with aptamers can be used as non-viral vectors for delivery of the anticancer agent camptothecin. (Mignani S, et al., 2020)

Our Services

As a fast-growing, leading global provider of scientific research services and solutions, CD BioSciences offers dendrimer-aptamer conjugation services based on our expertise and extensive experience in dendrimer research. Our talented scientists will meet all your detailed requirements, quickly provide the best solution for your research project, and ensure that all deliverables are subject to rigorous quality testing

Service Process

CD BioSciences is committed to helping our customers meet the growing and evolving demand for dendrimer products. We have been engaged in dendrimers research for a long time and have a comprehensive and mature technology platform to provide you with a wide range of services related to dendrites and excellent solutions for your research projects in a timely manner. If you are interested in our services or have any additional questions, please feel free to contact us, we are happy to hear from you and look forward to working with you.

Reference

1. Mignani S.;et al. Dendrimer- and polymeric nanoparticle-aptamer bioconjugates as nonviral delivery systems: a new approach in medicine. Drug Discov Today. 2020, 25: 1065-1073.